Patent expiration can change the very course of a market. In the case of the asthma therapeutics market however, the impact will be evident, but not devastating. Leading
brands will certainly suffer to a marked degree with the expiration of key drugs such as Singulair, Advair, and Symbicort. Despite this, the asthma
therapeutics market in the eight leading developed nations will likely brave the headwinds and register a CAGR of 2.4% between 2013 and 2020.
According to a recent research report, the market for asthma therapeutics was valued at US$18.4 billion as of 2013, and will expand to an estimated US$21.7
billion by the end of 2020. Moving forward, stakeholders and companies can expect a marginal rate of growth in the asthma therapeutics market, which can be
successfully sustained via the launch of innovative and affordable therapies.
Blow From Asthma Therapeutics Patent Expiration to be Softened by These Two Important Drivers
The restraining forces in the asthma therapeutics market will be balanced by two important drivers: The rising prevalence of asthma and new players
foraying into the market.
According to market research analysts, the number of people suffering from asthma in the world is pegged at to rocket to an alarming 400 million by 2025.
The sheer numbers of asthma patients, many of whom are located in increasingly affluent emerging economies, will create an organic demand for asthma
therapeutics. Encouraged by this hitherto untapped consumer base, several new entrants are expected to make their presence felt in the asthma therapeutics
These two factors will be important in the long run because they will prevent the market from reaching a point of stagnation.
Monoclonal Antibodies and Biologics to Attract Immense Interest from Pharmaceutical Industry
The current pool of asthma therapeutics is seen to be satisfactory in terms of helping patients manage symptoms. However, there are still some patients
that are unable to effectively control their condition using currently-available products. As a result, the asthma therapeutics market carries a small but
significant unmet need, which is further compounded by the pervasiveness of asthma. All of these factors have stirred the interest of pharmaceutical
companies in the asthma therapeutics industry.
Another factor that will greatly benefit the market is the presence of an asthma therapeutics pipeline teeming with novel molecules. Many of these
promising molecules are currently reported to be in the late-stage of development. Industry interest is particularly strong in monoclonal antibodies such
as lebrikizumab, mepolizumab, dupilumab and reslizumab – all of which directly target Interleukins receptors or ILs themselves. These therapies could
provide pioneering treatment for patients suffering from severe eosinophilic asthma not adequately controlled.
Personalized Therapy Carries Definite Revenue Generation Opportunity
Personalized therapy—though it caters to a small sub-set of patients—will be a trend to watch out for in the coming years. Given their high price tags,
revenues from personalized therapy drugs will be higher, and will possibly steer the market toward faster growth.
All of these factors will fuse together over the next few years to help alleviate the impact of patent expiration and the resultant generic erosion.
Browse the full Global Asthma Therapeutics Market report at http://www.mrrse.com/asthma-therapeutics-market